Abciximab: Difference between revisions
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
'''Abciximab''' (previously known as '''c7E3 Fab'''), a [[glycoprotein IIb/IIIa]] receptor antagonist manufactured by [[Janssen Biologics BV]] and distributed by [[Eli Lilly and Company|Eli Lilly]] under the trade name '''ReoPro''', is a [[platelet aggregation inhibitor]] mainly used during and after [[coronary artery]] procedures like [[angioplasty]] to prevent [[platelet]]s from sticking together and causing [[thrombus]] formation within the coronary artery. It is a [[glycoprotein IIb/IIIa inhibitor]]. | '''Abciximab''' (previously known as '''c7E3 Fab'''), a [[glycoprotein IIb/IIIa]] receptor antagonist manufactured by [[Janssen Biologics BV]] and distributed by [[Eli Lilly and Company|Eli Lilly]] under the trade name '''ReoPro''', is a [[platelet aggregation inhibitor]] mainly used during and after [[coronary artery]] procedures like [[angioplasty]] to prevent [[platelet]]s from sticking together and causing [[thrombus]] formation within the coronary artery. It is a [[glycoprotein IIb/IIIa inhibitor]]. | ||
<BR><BR> | <BR><BR> | ||
While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the [[platelet]]s, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the [[Fragment antigen binding|Fab]] fragments of an [[immunoglobulin]] that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.<ref name="INN">{{cite journal|url=http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list70.pdf|journal=WHO Drug Information|volume=7|issue=4|title=International Nonproprietary Names for Pharmaceutiical Substances|year=1993}}</ref> | While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the [[platelet]]s, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the [[Fragment antigen binding|Fab]] fragments of an [[immunoglobulin]] that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.<ref name="INN">{{cite journal|url=http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list70.pdf|journal=WHO Drug Information|volume=7|issue=4|title=International Nonproprietary Names for Pharmaceutiical Substances|year=1993}}</ref> | ||
| Line 35: | Line 35: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Abciximab is a chimeric human-murine monoclonal antibody F<sub>ab</sub> fragment which inhibits [[platelet aggregation]] by binding to the glycoprotein IIb/IIIa receptors on platelets. It prevents [[fibrinogen]] and [[von Willebrand factor]] from binding to the receptor in a dose-dependent manner. Abciximab may also bind to the [[vitronectin]] receptor and to the [[Mac-1]] receptor on activated [[monocytes]].<ref name="Faulds-1994">{{Cite journal | last1 = Faulds | first1 = D. | last2 = Sorkin | first2 = EM. | title = Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. | journal = Drugs | volume = 48 | issue = 4 | pages = 583-98 | month = Oct | year = 1994 | doi = | PMID = 7528131 }}</ref> | Abciximab is a chimeric human-murine monoclonal antibody F<sub>ab</sub> fragment which inhibits [[platelet aggregation]] by binding to the [[glycoprotein IIb/IIIa]] receptors on platelets. It prevents [[fibrinogen]] and [[von Willebrand factor]] from binding to the receptor in a dose-dependent manner. Abciximab may also bind to the [[vitronectin]] receptor and to the [[Mac-1]] receptor on activated [[monocytes]].<ref name="Faulds-1994">{{Cite journal | last1 = Faulds | first1 = D. | last2 = Sorkin | first2 = EM. | title = Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. | journal = Drugs | volume = 48 | issue = 4 | pages = 583-98 | month = Oct | year = 1994 | doi = | PMID = 7528131 }}</ref> | ||
==References== | ==References== | ||
Revision as of 23:49, 29 January 2014
Template:Abciximab Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2], Pratik Bahekar, MBBS [3]
For patient information, click here.
Overview
Abciximab (previously known as c7E3 Fab), a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.
While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.[1]
Category
Antiplatelet, Glycoprotein IIb/IIIa Receptor Antagonist
US Brand Names
ReoPro®
FDA Package Insert
Indications and Usage | Dosage and Administration | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Description | Clinical Pharmacology | Clinical Studies | How Supplied/Storage and Handling | Labels and Packages
Mechanism of Action
Abciximab is a chimeric human-murine monoclonal antibody Fab fragment which inhibits platelet aggregation by binding to the glycoprotein IIb/IIIa receptors on platelets. It prevents fibrinogen and von Willebrand factor from binding to the receptor in a dose-dependent manner. Abciximab may also bind to the vitronectin receptor and to the Mac-1 receptor on activated monocytes.[2]
References
- ↑ "International Nonproprietary Names for Pharmaceutiical Substances" (PDF). WHO Drug Information. 7 (4). 1993.
- ↑ Faulds, D.; Sorkin, EM. (1994). "Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease". Drugs. 48 (4): 583–98. PMID 7528131. Unknown parameter
|month=ignored (help)